| Literature DB >> 29403901 |
Qiong Wu1, Hai Zhang1, Xin Dong1, Xiao-Fei Chen1, Zhen-Yu Zhu1, Zhan-Ying Hong1, Yi-Feng Chai1.
Abstract
Hyperlipidemia is considered to be a high lipid level in blood, can induce metabolic disorders and dysfunctions of the body, and results in some severe complications. Therefore, hunting for some metabolite markers and clarifying the metabolic pathways in vivo will be an important strategy in the treatment and prevention of hyperlipidemia. In this study, a rat model of hyperlipidemia was constructed according to histopathological data and biochemical parameters, and the metabolites of serum and urine were analyzed by UPLC-Q-TOF/MS. Combining pattern recognition and statistical analysis, 19 candidate biomarkers were screened and identified. These changed metabolites indicated that during the development and progression of hyperlipidemia, energy metabolism, lipid metabolism, amino acid metabolism and nucleotide metabolism were mainly disturbed, which are reported to be closely related to diabetes, cardiovascular diseases, etc. This study demonstrated that a UPLC-Q-TOF/MS based metabolomic approach is useful to profile the alternation of endogenous metabolites of hyperlipidemia.Entities:
Keywords: Hyperlipidemia; Metabolomic; Pattern recognition; UPLC-Q-TOF/MS
Year: 2014 PMID: 29403901 PMCID: PMC5761356 DOI: 10.1016/j.jpha.2014.04.002
Source DB: PubMed Journal: J Pharm Anal ISSN: 2214-0883
Fig. 1Photomicrographs of hepatic tissue morphology of experimentally hyperlipidemic rats (×200). The features included (A) few fat droplets shown in the liver of normal control rats (NC) and (B) large fat droplets were indicated by the arrowhead in the liver of rats fed a high-fat diet (HFD).
Serum lipid levels of experimental hyperlipidemic rats induced by high-fat diet.
| Group | TC (mM) | TG (mM) | HDL-C (mM) | LDL-C (mM) | AI | HI |
|---|---|---|---|---|---|---|
| NC | 1.41±0.15 | 0.78±0.26 | 1.11±0.14 | 0.18±0.08 | 0.27±0.08 | 0.03±0.02 |
| HFD | 1.67±0.39 | 0.97±0.28 | 0.92±0.14 | 0.52±0.31 | 0.82±0.37 | 0.04±0.02 |
Values are expressed as mean ±SD, n=6.
TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein-cholesterol; and LDL-C, low-density lipoprotein-cholesterol.
p<0.05, compared with the control group (NC).
p<0.01, compared with the control group (NC).
Fig. 2Serum lipids profiles of the control group (NC) and the high-fat diet group (HFD). TC, total cholesterol; TG, triglyceride; HDLC, high-density lipoprotein cholesterol; and LDLC, low-density lipoprotein cholesterol. *p<0.05 vs. NC.
Fig. 3OPLS-DA score plot (top panel), loading plot (middle panel) and S-plot (bottom panel) of the UHPLC/TOF-MS spectra from the NC group (red triangle) and HFD group (blue box). (A: serum in ESI− mode; B: serum in ESI+ mode; C: urine in ESI− mode; and D: urine in ESI+ mode).
Identification of significantly differential metabolites in serum/urine of hyperlipidemic rats and their related metabolic pathway.
| No | TR(min) | Ion( | Adduct | Formula | Identification | Trend | Related pathway |
|---|---|---|---|---|---|---|---|
| 1 | 16.65 | 279.2344 | [M−H]− | C18H32O2 | Linoleic acid | ( | Fatty acid metabolism |
| 1 | 16.63 | 281.2481 | [M+H]+ | C18H32O2 | Linoleic acid | ( | Fatty acid metabolism |
| 2 | 16.51 | 303.2346 | [M−H]− | C20H32O2 | 8,11-Eicosadiynoic acid | ( | Fatty acid metabolism |
| 3 | 15.74 | 301.2182 | [M−H]− | C20H30O2 | EPA | ( | Fatty acid metabolism |
| 3 | 15.72 | 303.2321 | [M+H]+ | C20H30O2 | EPA | ( | Fatty acid metabolism |
| 4 | 9.83 | 453.2871 | [M+COO]− | C24H40O5 | Cholic acid | ( | Cholic acid biosynthesis |
| 5 | 15.12 | 275.2018 | [M−H]− | C18H28O2 | Stearidonic acid | ( | Fatty acid metabolism |
| 6 | 0.71 | 119.0894 | [M+H]+ | C4H6O4 | Succinic acid | ( | Citrate cycle |
| 7 | 13.96 | 274.6561 | [M+H]+ | C16H35NO2 | C16 Sphinganine | ( | Sphingolipid metabolism |
| 8 | 16.29 | 329.2479 | [M+H]+ | C22H32O2 | Docosahexaenoic acid | ( | Fatty acid metabolism |
| 9 | 10.09 | 302.2149 | [M+H]+ | C18H39NO2 | Sphinganine | ( | Sphingolipid metabolism |
| 10 | 5.89 | 178.0507 | [M−H]− | C9H9NO3 | Hippuric acid | ( | Phenylalanine metabolism |
| 10 | 5.85 | 180.0656 | [M+H]+ | C9H9NO3 | Hippuric acid | ( | Phenylalanine metabolism |
| 11 | 8.87 | 165.0557 | [M−H]− | C9H10NO3 | Phenyllactic acid | ( | Phenylalanine metabolism |
| 12 | 0.69 | 124.0075 | [M−H]− | C2H7NO3S | Taurine | ( | Taurine and hypotaurine metabolism |
| 13 | 0.77 | 166.0182 | [M+COO]− | C3H7NO2S | ( | Taurine and hypotaurine metabolism | |
| 14 | 8.88 | 166.0588 | [M+COO]− | C8H11NO3 | Norepinephrine | ( | Tyrosine metabolism |
| 15 | 0.72 | 132.0981 | [M+H]+ | C6H13NO2 | ( | Valine, leucine and isoleucine degradation | |
| 16 | 0.68 | 162.1121 | [M+H]+ | C7H15NO3 | ( | Carnitine synthesis | |
| 17 | 14.16 | 269.1387 | [M+NH4]+ | C10H13N5O3 | DHA | ( | Purine metabolism |
| 18 | 0.73 | 259.0932 | [M+H]+ | C10H14N2O6 | 3-Methyluridine | ( | Pyrimidine metabolism |
| 19 | 0.85 | 245.1295 | [M+H]+ | C9H12N2O6 | Uridine | ( | Pyrimidine metabolism |
Identified in serum under ESI−.
Identified in serum under ESI+.
Identified in urine under ESI−.
Identified in urine under ESI+.
Change trend compared with the control group. (↑): up-regulated and (↓): down-regulated.
Represents a statistically significant difference (p<0.05).
Fig. 4The integrative plot of the metabolites and the relevant pathways׳ changing for high-fat diet induced hyperlipidemia according to the KEGG PATHWAY database.